Samples (from blood, urine, etc.) are inspected and assigned an ID
Specific labeling of telomeres and disease specific proteins with fluorescent tags
Acquires consecutive images at consecutive focal planes across the depth of the sample to build one 3D image
1. # of Telomeres
2. Telomere lengths
3. Telomere aggregates
4. a:c Ratio
5. Nuclear volume
6. Position in nucleus
Personalized results that inform and guide treatment
Key publications of interest and with clinical relevance include Telo Genomics’ lead indication multiple myeloma, Alzheimer’s disease and prostate cancer.
- Tabs contain synopses of the key publications
- Below are the original publications
Telomere Architecture, Quantified Using TeloView® Technology Correlates with Aggressiveness in Multiple Myeloma, Smouldering Myeloma and MGUS Patients
Aline Rangel-Pozzo, Sherif Louis, Hans Knecht & Sabine Mail. Cancers. 2021, 13(8), 1969
TeloView® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma..
Sherif Louis, Hans Knecht & Sabine Mai. Blood. 2020, 136 (Supplement 1):19-20.
Distinct nuclear organization of telomeres and centromeres in monoclonal gammopathy of undetermined significance and myeloma.
Yu PLI & Mai S et al. Cells 8, 723, 2019.
Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.
Taylor-Kashton C & Mai S et al. XPO1 J Cell Physiol. 2016 Dec;231(12):2711-9.
3D nuclear telomere organization in multiple myeloma.
Klewes L & Mai S et al. Trans. Oncol. 2013 6(6): 749–756
Quantitative 3D telomeric imaging of buccal cells reveals Alzheimer’s disease-specific signatures.
Garcia A & Mai S et al. J Alzheimer’s Dis. 2017;58(1):139145.
Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate and severe Alzheimer patients. J of Alzheimer’s Disease.
Mathur S & Mai S et al. 2014 Jan 1;39(1):35-48.
Advancing risk assessment in intermediate risk prostate cancer patients.
Drachenberg D & Mai S et al. Cancers 11, 855, 2019
Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
Adebayo Awe J & Mai S et al. Urol Oncol. 2017 May;35(5):300309
3D telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations.
Awe JA & Mai S et al. Trans. Oncol. 2013 2013 Feb;6(1):51-65.